These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3706243)

  • 21. Exploring differences in drug doses between Japan and Western countries.
    Arnold FL; Kusama M; Ono S
    Clin Pharmacol Ther; 2010 Jun; 87(6):714-20. PubMed ID: 20410879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Placebo effects and adverse effects in clinical trials].
    Weihrauch TR
    Med Klin (Munich); 2000 May; 95(1 Spec No):23-30. PubMed ID: 10851845
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Is the placebo still ethically acceptable and scientifically useful in clinical drug experimentation?].
    Mariani L; Ventresca GP
    Clin Ter; 1996 Nov; 147(11):595-8. PubMed ID: 9264914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Placebo-controlled trials and the logic of clinical purpose.
    Freedman B
    IRB; 1990; 12(6):1-6. PubMed ID: 11651265
    [No Abstract]   [Full Text] [Related]  

  • 25. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Dose-response relationship: relevance for medical practice].
    Klinkhardt U; Harder S
    Med Klin (Munich); 2000 May; 95(1 Spec No):9-14. PubMed ID: 10851842
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Avoiding adverse reactions. Effective lower-dose drug therapies for older patients.
    Cohen JS
    Geriatrics; 2000 Feb; 55(2):54-6, 59-60, 63-4. PubMed ID: 10711307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Drug interaction studies: study design, data analysis, and implications for dosing and labeling.
    Huang SM; Temple R; Throckmorton DC; Lesko LJ
    Clin Pharmacol Ther; 2007 Feb; 81(2):298-304. PubMed ID: 17259955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Ethics and clinical trials].
    Abadie E
    Encephale; 1990; 16(4):275-6. PubMed ID: 2209481
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Are children getting the right drugs?].
    Bratlid D
    Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3290-2. PubMed ID: 16327857
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose finding - a challenge in statistics.
    Bretz F; Hsu J; Pinheiro J; Liu Y
    Biom J; 2008 Aug; 50(4):480-504. PubMed ID: 18663758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Statistical considerations in clinical field evaluation of drugs.
    Powers JD; Powers TE
    J Am Vet Med Assoc; 1980 May; 176(10 Spec No):1151-2. PubMed ID: 7216891
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating potential benefits of dose-exposure-response modeling for dose finding.
    Hsu CH
    Pharm Stat; 2009; 8(3):203-15. PubMed ID: 19629954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo controls in clinical trials of new therapies for osteoporosis.
    Levine RJ
    J Bone Miner Res; 2003 Jun; 18(6):1154-9. PubMed ID: 12817775
    [No Abstract]   [Full Text] [Related]  

  • 35. The use of one-sided tests in drug trials: an FDA advisory committee member's perspective.
    Fisher LD
    J Biopharm Stat; 1991; 1(1):151-6. PubMed ID: 1844686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The rationale for placebo-controlled trials: methodology and policy considerations.
    Miller FG
    Am J Bioeth; 2009 Sep; 9(9):49-50. PubMed ID: 19998193
    [No Abstract]   [Full Text] [Related]  

  • 37. Assessing dose-region profile of drug efficacy: a multiregional trial strategy.
    Chen YH; Wang M
    J Biopharm Stat; 2012 Sep; 22(5):894-902. PubMed ID: 22946938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The need for modeling and simulation to design clinical investigations in children.
    Jadhav PR; Kern SE
    J Clin Pharmacol; 2010 Sep; 50(9 Suppl):121S-129S. PubMed ID: 20881225
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Approaches to Japanese dose evaluation in global drug development: factors that generate different dosages between Japan and the United States.
    Nakashima K; Narukawa M; Takeuchi M
    Clin Pharmacol Ther; 2011 Dec; 90(6):836-43. PubMed ID: 22048222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A proof-of-concept clinical trial design combined with dose-ranging exploration.
    Wang X; Ting N
    Pharm Stat; 2012; 11(5):403-9. PubMed ID: 22714951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.